Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Jan 2023
Historique:
received: 08 05 2022
entrez: 28 1 2023
pubmed: 29 1 2023
medline: 1 2 2023
Statut: epublish

Résumé

Nasopharyngeal carcinoma (NPC) is a severe malignant disease. Despite its low frequency, NPC is very common in North African population. Radiotherapy is the standard therapeutic treatment of NPC. However, radioresistance hampers the success of treatment. At the molecular scale, radioresistance is due to genetic variations involved in DNA repair pathways in NPC patients. Several studies reported that single nucleotide polymorphisms (SNPs) in excision repair cross complementing group 1 (ERCC1) could be associated with radioresistance. In this optic, the present study aimed to evaluate the association between DNA repair gene polymorphisms ERCC1 C8092A and ERCC1 C118T and radiotherapy response of patients with NPC. A total of 95 patients with confirmed NPC were recruited at the Mohammed VI Center for Cancer Treatment, Casablanca - Morocco between 2016 and 2018. Two single nucleotide polymorphisms in ERCC1 gene were genotyped. Multiple analysis software was used to assess the correlation between these SNPs and radio-therapeutic response. Sequencing of ERCC1 C8092A polymorphism revealed that CC and CA genotypes were found in 51.6% and 45.3% of cases, respectively, whereas the homozygote AA genotype was reported in only 3.1% of cases. For ERCC1 C118T polymorphism, the heterozygote CT genotype was identified in 49.5% of cases. Homozygotes genotypes CC and TT were detected in 17.9% and 32.6% respectively of NPC cases. Of note, no significant association was found between the ERCC1 C8092A polymorphism and response to radiation therapy (p=0.81). Similarly, there was no significant association between the response to radiotherapy and allelic distribution (p=0.56). Likewise, no correlation was observed neither with genotypes (p=0.07) nor with alleles (p=0.09) of ERCC1 C118T polymorphism and response to radiation therapy. Our results clearly showed that ERCC1 C8092A and ERCC1 C118T polymorphisms were not associated with response to radiotherapy in Moroccan NPC patients. Large studies are warranted to confirm the role of these SNPs in therapeutic response of NPC patients.

Identifiants

pubmed: 36708557
doi: 10.31557/APJCP.2023.24.1.93
pmc: PMC10152845
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
Endonucleases EC 3.1.-
ERCC1 protein, human EC 3.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

93-99

Références

Clin Transl Oncol. 2015 Sep;17(9):710-9
pubmed: 26022132
J Radiat Res. 2021 May 12;62(3):438-447
pubmed: 33783535
Eur Arch Otorhinolaryngol. 2020 Feb;277(2):601-610
pubmed: 31749055
J Gastrointest Surg. 2009 Aug;13(8):1411-21
pubmed: 19421825
PLoS One. 2011;6(5):e20055
pubmed: 21647442
Biomed Rep. 2014 Jul;2(4):452-462
pubmed: 24944789
Mol Carcinog. 2009 Mar;48(3):196-201
pubmed: 18615480
Adv Exp Med Biol. 2019;1164:11-34
pubmed: 31576537
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1022-30
pubmed: 16979838
Mol Carcinog. 2012 Jul;51(7):546-52
pubmed: 21739480
Br J Radiol. 2019 Oct;92(1102):20190244
pubmed: 31298937
Cancer Med. 2018 Dec;7(12):6317-6330
pubmed: 30453383
Cancer Res. 1998 Feb 15;58(4):604-8
pubmed: 9485007
Sci Rep. 2016 Jun 01;6:26526
pubmed: 27246533
Int J Mol Sci. 2020 Jun 16;21(12):
pubmed: 32560253
Clin Cancer Res. 2004 Aug 1;10(15):4939-43
pubmed: 15297394
BMC Med Genet. 2018 Jul 6;19(1):112
pubmed: 29980176
Cell Death Dis. 2018 Feb 14;9(2):235
pubmed: 29445147
Oncotarget. 2017 Dec 5;9(1):958-968
pubmed: 29416669
Oncotarget. 2016 Mar 8;7(10):11463-77
pubmed: 26862850
Med Oncol. 2011 Mar;28(1):315-21
pubmed: 20143185
Br J Radiol. 2019 Oct;92(1102):20199004
pubmed: 31526301
Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6
pubmed: 16224397
Cancer Radiother. 2019 Dec;23(8):883-890
pubmed: 31615730
Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):948-957
pubmed: 32007367
Pharmacogenomics J. 2012 Dec;12(6):476-83
pubmed: 21826087
Genet Mol Res. 2016 May 23;15(2):
pubmed: 27323074
Mol Med Rep. 2011 Sep-Oct;4(5):771-7
pubmed: 21687948
Cancer Chemother Pharmacol. 2013 Aug;72(2):315-22
pubmed: 23712330
Crit Rev Eukaryot Gene Expr. 2017;27(3):267-275
pubmed: 29199611
PLoS One. 2014 Jul 15;9(7):e101256
pubmed: 25025378
Cancer Radiother. 2019 Oct;23(6-7):666-673
pubmed: 31451357
Oncotarget. 2015 Oct 13;6(31):32193-204
pubmed: 26320178
Oral Oncol. 2017 Apr;67:70-76
pubmed: 28351583
J Thorac Dis. 2021 May;13(5):3126-3136
pubmed: 34164203
Iran J Pharm Res. 2019 Fall;18(4):2163-2171
pubmed: 32184881
Cell Mol Life Sci. 2020 Feb;77(4):677-703
pubmed: 31612241

Auteurs

Rajaa Benzeid (R)

Biology and Medical Research Unit, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.
Laboratory of Microbiology and Molecular Biology, Faculty of Sciences, Rabat, Morocco.

Amina Gihbid (A)

Laboratory of Viral Oncology, Institut Pasteur du Maroc, Casablanca, Morocco.

Nezha Tawfiq (N)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Nadia Benchakroun (N)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Karima Bendahhou (K)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Abdelatif Benider (A)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Amal Guensi (A)

Nuclear Medecine Department, Ibn Rochd University Hospital, Hassan II University, Casablanca, Morocco.

Naima El Benna (N)

Department of Radiology, Ibn Rochd University Hospital, Hopital 20 Août, Casablanca, Morocco.

Abdelkarim Filali Maltouf (A)

Laboratory of Microbiology and Molecular Biology, Faculty of Sciences, Rabat, Morocco.

Mohammed Attaleb (M)

Biology and Medical Research Unit, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.

Imane Chaoui (I)

Biology and Medical Research Unit, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.

Meriem Khyatti (M)

Laboratory of Viral Oncology, Institut Pasteur du Maroc, Casablanca, Morocco.

Mohammed El Mzibri (M)

Biology and Medical Research Unit, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH